Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025
Rapid Micro Biosystems (Nasdaq: RPID) has scheduled the release of its fourth quarter and full year 2024 financial results before market opening on February 28, 2025. The company, which specializes in providing automation solutions for healthcare product manufacturing, will accompany the results announcement with a webcast conference call hosted by the management team at 8:00 a.m. ET on the same day. The webcast will be available on the company's website and will remain accessible for replay after the event.
Rapid Micro Biosystems (Nasdaq: RPID) ha programmato la pubblicazione dei suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 prima dell'apertura del mercato il 28 febbraio 2025. L'azienda, specializzata nella fornitura di soluzioni di automazione per la produzione di prodotti sanitari, accompagnerà l'annuncio dei risultati con una conferenza telefonica in webcast ospitata dal team di gestione alle 8:00 a.m. ET lo stesso giorno. Il webcast sarà disponibile sul sito web dell'azienda e rimarrà accessibile per la riproduzione dopo l'evento.
Rapid Micro Biosystems (Nasdaq: RPID) ha programado la publicación de sus resultados financieros del cuarto trimestre y del año completo 2024 antes de la apertura del mercado el 28 de febrero de 2025. La empresa, que se especializa en proporcionar soluciones de automatización para la fabricación de productos de salud, acompañará el anuncio de resultados con una llamada de conferencia por webcast dirigida por el equipo de gestión a las 8:00 a.m. ET el mismo día. El webcast estará disponible en el sitio web de la empresa y permanecerá accesible para su reproducción después del evento.
Rapid Micro Biosystems (Nasdaq: RPID)는 2025년 2월 28일 시장 개장 전에 2024년 4분기 및 연간 재무 결과 발표를 예정하고 있습니다. 헬스케어 제품 제조를 위한 자동화 솔루션 제공을 전문으로 하는 이 회사는 같은 날 오전 8:00 ET에 경영진이 주최하는 웹캐스트 컨퍼런스 콜과 함께 결과 발표를 진행할 예정입니다. 웹캐스트는 회사 웹사이트에서 이용 가능하며 이벤트 후에도 재생할 수 있습니다.
Rapid Micro Biosystems (Nasdaq: RPID) a prévu la publication de ses résultats financiers du quatrième trimestre et de l'année complète 2024 avant l'ouverture du marché le 28 février 2025. L'entreprise, spécialisée dans la fourniture de solutions d'automatisation pour la fabrication de produits de santé, accompagnera l'annonce des résultats par une conférence téléphonique en webcast animée par l'équipe de direction à 8h00 ET le même jour. Le webcast sera disponible sur le site internet de l'entreprise et restera accessible pour une rediffusion après l'événement.
Rapid Micro Biosystems (Nasdaq: RPID) hat die Veröffentlichung seiner Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 vor der Markteröffnung am 28. Februar 2025 angesetzt. Das Unternehmen, das sich auf Automatisierungslösungen für die Herstellung von Gesundheitsprodukten spezialisiert hat, wird die Ergebnisankündigung mit einer Webcast-Konferenzschaltung begleiten, die am selben Tag um 8:00 Uhr ET vom Management-Team geleitet wird. Der Webcast wird auf der Unternehmenswebsite verfügbar sein und bleibt nach der Veranstaltung für eine Wiederholung zugänglich.
- None.
- None.
LEXINGTON, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2024 financial results prior to the market open on Friday, February 28, 2025.
In conjunction with the release, the Company’s management team will host a webcast conference call at 8:00 a.m. ET on Friday, February 28, 2025. The live audio webcast will be accessible on the Company’s website and can be accessed with this link. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
FAQ
When will Rapid Micro Biosystems (RPID) release Q4 and full year 2024 earnings?
What time is RPID's Q4 2024 earnings conference call?
How can investors access RPID's Q4 2024 earnings webcast?
Will RPID's Q4 2024 earnings call be available for replay?
